RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 mg and Submission to FDA of IBS-D Phase II Study Protocol Feb 12, 2016
RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn’s Disease Program Feb 11, 2016
RedHill Biopharma Announces Collaboration with Germany’s Fraunhofer Institute for Oncology Drug RP101 Feb 9, 2016
Resverlogix’s Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal Jan 26, 2016
Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference Nov 10, 2015
Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey Oct 20, 2015
Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases Sep 25, 2015
Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 ‘apabetalone’ a Selective BET Inhibitor Sep 1, 2015
International Clinical Steering Committee Announced for Resverlogix’s Phase 3 BETonMACE Clinical Trial with RVX-208 “apabetalone” Aug 5, 2015
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink Jul 9, 2015
